Improving HIV testing and care for men using U=U messaging

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of U=U messaging and counseling to address gaps in the HIV care cascade for men in South Africa. It aims to increase HIV testing uptake, encourage initiation of antiretroviral treatment (ART), and improve retention in care and viral suppression among men living with HIV. The study will utilize a multi-method evaluation to inform future implementation of U=U messaging interventions. By focusing on the unique barriers faced by men, the study seeks to enhance their health outcomes and contribute to the global goals for HIV treatment and prevention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

AIM 1:

1. male
2. aged ≥15 years
3. present a study issued invitation card to site receptionist
4. ability to provide informed consent.

AIM 2:

1. cis-gender men
2. aged ≥15 years
3. newly initiating ART (i.e., treatment naïve) or re-initiating ART after 6 months of being lost-to-care
4. live in Buffalo City or Cape Town Metro Health Districts
5. provide written informed consent

Where it's running

• Buffalo City Metro
  East London, Eastern Cape, South Africa Recruiting
• Cape Town Metro
  Cape Town, Western Cape, South Africa Recruiting

Study contacts

• Principal investigator: Andrew Medina-Marino, PhD — Desmond Tutu Health Foundation
• Study coordinator: Andrew Medina-Marino, PhD
• Email: Andrew.Marino@hiv-research.org.za
• Phone: +27 87 821 1109

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Camino HIV Prevention and Care Study

  This study tests a combined legal and peer-support program to help Latin American adults in DC and the Bay Area improve HIV testing, PrEP use, and care engagement.

  Recruiting American University · Berkeley, California and 1 other locations · NCT07834853

• VH4367310 in healthy adults: testing single increasing doses for safety and how it behaves in the body

  This study tests a single rising dose of VH4367310, a cabotegravir prodrug, to see how it behaves in the body and how safe and tolerable it is in healthy adults aged 18 to 55.

  Recruiting at 2 sites Phase 1 ViiV Healthcare · Glendale, California and 1 other locations · NCT07818915

• Online cohort of sexual and gender minorities testing digital support to boost PrEP and ART use

  In Brazil, sexually and gender diverse adults are being followed online to see if weekly WhatsApp reminders help people stick to PrEP or ART.

  Recruiting Oswaldo Cruz Foundation · Rio de Janeiro, Rio de Janeiro · NCT07772791

• Metabolic Liver Disease in People Newly Diagnosed with HIV

  This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.

  Recruiting at 11 sites Guven Health Group · Ankara, Ankara and 10 other locations · NCT07737340

• Screen2Prevent: HIV screening for teens and young adults in emergency departments

  The study tests three ways of offering HIV screening to people aged 14–24 in emergency departments to see if it helps link them to PrEP or HIV treatment using digital health tools.

  Recruiting at 5 sites Westat · Tampa, Florida and 4 other locations · NCT07728123

• Impact of Food Help on Adherence to Cancer Treatment

  This study tests whether providing food assistance helps adults with cancer who have food insecurity stick to their treatment plans.

  Recruiting Virginia Commonwealth University · Richmond, Virginia · NCT07706192

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.